Emergent BioSolutions initiates Phase Ib chronic lymphocytic leukemia studyEquities.comNov 02, 2012 (Datamonitor via COMTEX) — Emergent BioSolutions Inc., a biopharmaceutical company, has announced the initiation of a Phase Ib study, or Protocol 16009…
Emergent advances leukemia therapy to next trial stageGazette.Net: Maryland Community News OnlineThe trial, which will enroll about 24 patients who have not been treated for chronic lymphocytic leukemia, is designed to test the safety and efficacy of T…
Cell Therapeutics, Inc. (CTI) Reduces Net Loss for Third Quarter and Nine …Sacramento BeeThe European Medicines Agency's (the "EMA") Committee for Medicinal Products for Human Use has accepted PIX306, CTI's ongoing randomized contro…
Cell Therapeutics, Inc. (CTI) Reduces Net Loss for Third Quarter and Nine …The Herald | HeraldOnline.comThe European Medicines Agency's (the "EMA") Committee for Medicinal Products for Human Use has accepted PIX306, CTI's ongoing ra…
OncLiveSmall-Molecule Inhibitors Hold Promise for Elderly CLL PatientsOncLiveWierda noted that a phase II study is currently under way for patients ≥65 years with previously untreated CLL who will receive GS-1101 in combination with rituximab versus …
Survey: Many docs will be slow to switch to biosimilar mAbsFierceBiotechBut there was a distinct hesitancy noted in the U.S. when the conversation turned to the first generation of biosimilars for the monoclonal antibodies like rituximab (Roche's (…
Benlysta will be lupus market leader in 2021 with sales of more than $1.7 …The Pharma LetterThe off-label use of two high-priced agents – the biologic rituximab (Biogen Idec/Roche/Chugai/Zenyaku Kogyo's Rituxan, Roche's MabThera) and the immu…
Out of the Red and into the Black: John McCamant on Investment inJutia GroupWe have seen Celgene Corp. (CELG:NASDAQ) target multiple myeloma with Revlimid (lenalidomide), and we've seen other drugs in this space, such as Genentech/Roche Holding AG&…
BioTrends Research GroupPosted on:25 Oct 12PharmiWeb.com (press release)Despite initial hesitancy to prescribe biosimilar monoclonal antibodies, the market opportunity for biosimilar versions of rituximab, trastuzumab, cetuximab, and bevacizumab are fo…
Biogen Idec Increases Revenue 6 percent to $1.4 Billion in the Third QuarterThe Herald | HeraldOnline.comRITUXAN® (rituximab) revenues from our unconsolidated joint business arrangement were $288 million for the quarter, an increase of 8 percent year-…